0001171843-26-001890
SEC filingBeyondSpring Inc. announced financial results for the full year ended December 31, 2025, reporting net loss from continuing operations of $8.7 million and cash, cash equivalents, and short-term investments of $12.6 million. The company highlighted Phase 3 survival benefits for Plinabulin in EGFR wild-type NSCLC from the DUBLIN-3 study and plans for the confirmatory DUBLIN-4 trial.